Med24
metabolsk-terapi 1. 9. 2026 • 2 min read • Journal of veterinary internal medicine (PubMed)

Effekt av Canagliflozin på Insulinsensitive i Insulin-dysregulerte Hester

En randomisert studie undersøkte effekten av legemidlet canagliflozin (CAN) på insulin-dysregulerte hester. Resultatene viste en endret respons på insulin, inkludert redusert insulin-sensitivitet og økt insulinmetabolisme, noe som kan påvirke glykemisk kontroll.

Illustration représentant l'équilibre hormonal perturbé dans les maladies cardio-rénovas-métaboliques, mettant en évidence le rôle du cortisol.

The study investigated the effects of canagliflozin (CAN) on insulin-dysregulated (ID) horses. The research aimed to determine the impact of CAN on insulin sensitivity, insulin clearance, and β-cell responsiveness. Twenty privately owned ID mares participated in a randomized, double-blind, placebo-controlled trial. Horses were administered either CAN (0.4 mg/kg once daily) or a placebo for four weeks. Assessments were conducted using a euglycemic hyperinsulinemic clamp (EHC) to measure insulin sensitivity and insulin metabolic clearance rate (MCR), and a graded glucose infusion test (GGI) to evaluate β-cell responsiveness. Results indicated that insulin sensitivity (M/I) was lower with CAN compared to the placebo group (1.5 ± 0.2 mg/kg/min × 103 / [μIU/mL] versus 2.7 ± 0.2 mg/kg/min × 103 / [μIU/mL]); the least squares mean difference was -1.3 [95% CI, -1.9 to -0.6]; P < 0.001). Conversely, insulin MCR was significantly higher in the CAN group (6.5 ± 0.3 mL/kg/min versus 5.4 ± 0.3 mL/kg/min); the least squares mean difference was 1.0 [95% CI, 0.3-1.8]; P = 0.01). Furthermore, β-cell responsiveness (ΔI versus ΔG) was 43.3% lower with CAN (20.8 [95% CI, 16.9-25.5] mIU/mmol versus 36.7 [29.9-45.1] mIU/mmol); the ratio of geometric least squares means was 0.57 [95% CI, 0.42-0.76]; P < 0.001). The study concluded that β-cell responsiveness was reduced and insulin clearance was increased in the CAN-treated horses, despite apparent lower insulin sensitivity. The research suggests that higher endogenous glucose production in the CAN-treated mares may have contributed to an underestimation of insulin sensitivity.

Sponsored content

Original Scientific Source
Journal of veterinary internal medicine (PubMed)
View Original Source
Medisinsk ansvarsfraskrivelse Alle beregninger, råd og tolkninger på dette nettstedet er kun ment til informasjons- og opplysningsformål. De erstatter ikke profesjonell medisinsk undersøkelse, diagnose eller behandling. Rådfør deg alltid med lege ved helsespørsmål.

Recommended Medical News

All news →
Nanoteknologi-basert 18F-FDG-avbildning for å forstå endringer i insulinfølsomhet: Nåværende bevis, metodologiske hull og overføringsutfordringer
metabolsk-terapi

Nanoteknologi-basert 18F-FDG-avbildning for å forstå endringer i insulinfølsomhet: Nåværende bevis, metodologiske hull og overføringsutfordringer

Insulinresistens er et betydelig metabolske problem knyttet til tilstander som type 2 diabetes, fedme og metabolske syndromer. 18F-FDG PET-avbildning, drevet av nanoteknologi, gir et ikke-invasivt verktøy for å analysere glukosemetabolismen i vev. Denne studien undersøker nåværende bevis, metodologiske utfordringer og potensielle overføringsbarrierer knyttet til denne tilnærmingen.

10. 11. 2026 Read article →
Advertisement